Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Strong Long who wrote (1810)

4/1/2016 7:35:02 PM

From: mokelumne river

Read Replies (1) | Respond to of 2026

SL, by 2017 we will know if the FDA approves or not. If it approves and Pfizer decides to market Vitaros in the US, the company will get a chunk of change...not the full $25M but hopefully a significant amount. By 2017 I agree that the company expects sales milestones from Europe (see below). So after streamlining, and with milestone payments, I can see that 2017 might be profitable. Just a reminder on the level of the sales milestones, they are listed in the third numbers column. That is a lot of change in the company's pocket if and when any of those sales milestones are realized. This table is from page 9 of the recent 10K. Of course, it would be nice to know what level of sales would trigger any of these milestone payments.

sec.gov

Sandoz	$	319	$	1,500	$	45,613	$	47,432
Recordati	—		1,093		37,692		38,785
Takeda	437		—		36,600		37,037
Allergan	—		25,000		—		25,000
Majorelle	2,000		—		16,934		18,934
Ferring	2,000		—		14,000		16,000
Mylan	225		—		13,000		13,225
Bracco	—		—		4,916		4,916
Neopharm	250		—		4,000		4,250
Elis	100		—		1,900		2,000